Business Description
Jazz Pharmaceuticals PLC
NAICS : 325412
SIC : 2834
ISIN : IE00B4Q5ZN47
Total Employee Number:
2,890Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.53 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 1.2 | |||||
Debt-to-EBITDA | 8.02 | |||||
Interest Coverage | 5.02 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.95 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.1 | |||||
3-Year EBITDA Growth Rate | -20.8 | |||||
3-Year EPS without NRI Growth Rate | -14.1 | |||||
3-Year FCF Growth Rate | 14.9 | |||||
3-Year Book Growth Rate | 12.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 45.37 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.23 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.45 | |||||
9-Day RSI | 63.59 | |||||
14-Day RSI | 61.13 | |||||
3-1 Month Momentum % | 25.71 | |||||
6-1 Month Momentum % | 39.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.04 | |||||
Quick Ratio | 1.85 | |||||
Cash Ratio | 1.28 | |||||
Days Inventory | 319.98 | |||||
Days Sales Outstanding | 62.47 | |||||
Days Payable | 76.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.9 | |||||
Shareholder Yield % | 3.09 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88 | |||||
Operating Margin % | 20.5 | |||||
Net Margin % | 0.66 | |||||
EBITDA Margin % | 15.21 | |||||
FCF Margin % | 25.73 | |||||
OCF Margin % | 30 | |||||
ROE % | 0.71 | |||||
ROA % | 0.26 | |||||
3-Year ROIIC % | 0.27 | |||||
ROC (Joel Greenblatt) % | -4.97 | |||||
ROCE % | -0.4 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 9.2 | |||||
PE Ratio without NRI | 32.55 | |||||
Shiller PE Ratio | 53.03 | |||||
PS Ratio | 3.39 | |||||
PB Ratio | 3.33 | |||||
Price-to-Free-Cash-Flow | 13.26 | |||||
Price-to-Operating-Cash-Flow | 11.33 | |||||
EV-to-EBIT | -470.34 | |||||
EV-to-Forward-EBIT | 15.83 | |||||
EV-to-EBITDA | 26.19 | |||||
EV-to-Forward-EBITDA | 9.98 | |||||
EV-to-Revenue | 3.98 | |||||
EV-to-Forward-Revenue | 3.91 | |||||
EV-to-FCF | 15.46 | |||||
Price-to-GF-Value | 1.6 | |||||
Price-to-Projected-FCF | 1.13 | |||||
Price-to-Median-PS-Value | 1.09 | |||||
Earnings Yield (Greenblatt) % | -0.21 | |||||
FCF Yield % | 7.55 | |||||
Forward Rate of Return (Yacktman) % | -4.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jazz Pharmaceuticals PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,813.702 | ||
| EPS (TTM) (€) | -0.13 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 61.13 | ||
| 14-Day ATR (€) | 4.103737 | ||
| 20-Day SMA (€) | 199.1175 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 113.55 - 209.5 | ||
| Shares Outstanding (Mil) | 62.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jazz Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jazz Pharmaceuticals PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 128 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 127 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 35 days | ||
| General meeting for 2026 | 2026-07-24 09:45 | In 24 days | ||
| Guidance call for 2026 | 2026-06-03 10:30 | 199.25 (+0.00%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit | 2026-05-27 14:00 | 208.10 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-19 08:00 | 192.90 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 16:30 | 170.90 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 170.90 (+0.00%) |
Show
Entries
Jazz Pharmaceuticals PLC Frequently Asked Questions
What is Jazz Pharmaceuticals PLC(HAM:J7Z)'s stock price today?
The current price of HAM:J7Z is €209.50. The 52 week high of HAM:J7Z is €209.50 and 52 week low is €113.55.
When is next earnings date of Jazz Pharmaceuticals PLC(HAM:J7Z)?
The next earnings date of Jazz Pharmaceuticals PLC(HAM:J7Z) is 2026-08-05 Est..
Does Jazz Pharmaceuticals PLC(HAM:J7Z) pay dividends? If so, how much?
Jazz Pharmaceuticals PLC(HAM:J7Z) does not pay dividend.
Press Release
Articles on Jazz Pharmaceuticals PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers